Latest Market News

Stay updated with the latest market and industry news from across global sectors. We cover key developments, policy changes, and business updates that matter. Trusted news to help professionals stay informed and competitive.
Filter by Category
Aerospace and Defense
Automotive & Transportation
Banking, Financial Services, and Insurance
Chemicals & Materials
Consumer Goods
Electronics & Semiconductors
Energy & Power
Food & Beverages
Life Sciences
Manufacturing & Construction
Technology, Media, and Telecommunications

Reo.Dev Expands U.S. Presence With AI-Powered GTM Tools

Reo.Dev AI platform is gaining attention after the company expanded its U.S. operations and launched new AI-driven capabilities. The platform focuses on helping businesses understand how developers evaluate software products. It brings a fresh approach...

Publication Date: May 27, 2026    |    Author Name: Preety Shaha    |    Industry: Technology, Media, and Telecommunications

EU Approves PYRUKYND (mitapivat) for Adult Thalassemia Care

The European Commission has approved PYRUKYND (mitapivat) for adults living with alpha- or beta-thalassemia across European Union member states. The decision marks a significant milestone because PYRUKYND becomes the only approved medicine in Europe for...

Publication Date: May 26, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

Nuclear Medicine: Transforming Modern Diagnostic Imaging

Modern healthcare continues to evolve rapidly, and nuclear medicine now stands at the forefront of diagnostic innovation. It provides a unique blend of functional imaging and clinical precision, enabling clinicians to detect diseases earlier and...

Publication Date: May 26, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

FDA Approves Datopotamab Deruxtecan-Dlnk for TNBC

The U.S. Food and Drug Administration approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer (TNBC). The approval targets patients who are not candidates for PD-1 or PD-L1 inhibitor therapy. Consequently, the...

Publication Date: May 25, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

Bugcrowd RL Environments launch to advance real-world AI security training

Bugcrowd RL Environments has entered the cybersecurity market with a strong push toward real-world AI training. The company introduced this new solution to help developers train models using actual software vulnerabilities. It aims to bring...

Publication Date: May 22, 2026    |    Author Name: Preety Shaha    |    Industry: Technology, Media, and Telecommunications

ICF Launches Agentic AI Accelerator for Government Agencies

Agentic AI for government agencies is gaining traction as ICF launches a new accelerator to modernize public operations. The company introduced the ICF AI accelerator to improve licensing, permitting, and inspections processes. This solution combines...

Publication Date: May 21, 2026    |    Author Name: Preety Shaha    |    Industry: Technology, Media, and Telecommunications

Domino Data Lab Launches Tools to Scale Enterprise AI Applications

Domino Data Lab AI platform is advancing enterprise adoption as the company introduced new tools designed to turn AI models into real business applications. With the Domino Data Lab AI platform, organizations can now build,...

Publication Date: May 20, 2026    |    Author Name: Preety Shaha    |    Industry: Technology, Media, and Telecommunications

Regeneron–Parabilis Medicines to Advance Antibody-Helicon Conjugates

Regeneron Pharmaceuticals announced a strategic collaboration with Parabilis Medicines to develop cutting-edge therapies. The agreement centers on antibody-Helicon conjugates, a novel approach designed across multiple therapeutic areas to target intracellular proteins that traditional therapies cannot...

Publication Date: May 19, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

FDA Approves fam-trastuzumab deruxtecan-nxki in Breast Cancer for HER2 Therapy

The U.S. Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki for two new indications in HER2-positive early-stage breast cancer treatment. Additionally, the decision significantly broadens the role of fam-trastuzumab deruxtecan-nxki in curative-intent care settings across earlier...

Publication Date: May 18, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

Lilly–UNICEF Expand Non-Communicable Disease Care

A major global collaboration has launched to improve non-communicable disease prevention and treatment for children. The six-year initiative aims to reach more than 30 million children, adolescents, and caregivers across 21 low- and middle-income countries.The...

Publication Date: May 15, 2026    |    Author Name: Mursalin Pathan    |    Industry: Life Sciences

 
    News 1 to 10  | Total Count : 370
  • 1
    •  2 3 »  Last
© The News and Media Division of The Insight Partners 2026 | All Rights Reserved | Privacy Policy